Several preclinical studies have demonstrated anti-tumor effects in wild-type TP53 tumors using novel inhibitors of negative regulators, such as inhibitors of MDM2/MDMX, in melanoma cell lines and animal xenografts. This evidence concerns the gene MDM2 and neoplasm.